Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

76 results about "CCL2" patented technology

The chemokine (C-C motif) ligand 2 (CCL2) is also referred to as monocyte chemoattractant protein 1 (MCP1) and small inducible cytokine A2. CCL2 is a small cytokine that belongs to the CC chemokine family. CCL2 recruits monocytes, memory T cells, and dendritic cells to the sites of inflammation produced by either tissue injury or infection.

Method for efficiently separating and preparing exosome

The invention relates to the technical field of biomedicine, in particular to a method for efficiently separating and preparing exosomes, which comprises the following steps: S10, providing human umbilical cord mesenchymal stem cells; s20, culturing the human umbilical cord mesenchymal stem cells by using an exosome induction culture medium; the exosome induction culture medium contains a first inflammatory factor; a second inflammatory factor is added in the culture process; the first inflammatory factor comprises at least one selected from the following groups: IL-6 and TNF-alpha; the second inflammatory factor comprises CCL2; and S30, collecting the supernatant of the culture medium in the step S20, and centrifugally collecting to obtain the exosome. The method can improve the yield of the exosomes, has the advantage of simple operation, is suitable for extracting a large amount of exosomes, and has a good clinical application prospect.
Owner:JIANGXI HANS UNITED STEM CELL TECH CO LTD

Application of Paquinimod in preparation of medicine for treating secondary lymphedema

The invention is applicable to the technical field of biological medicines, and provides application of Paquinimod in preparation of a medicine for treating secondary lymphedema. According to the application, the S100A8 / A9 dimer small-molecule inhibitor Paquinimod is used for treating mice with lymphedema, and a result shows that the Paquinimod can be used for remarkably inhibiting secretion of inflammatory factors of the model mice, effectively relieving the edema condition and inhibiting activation of an S100A8 / A9-TLR4-CCL2 signal channel. Therefore, the inhibitor Paquinimod of the S100A8 / A9-TLR4 signal channel is applied to preparation of the medicine for treating the secondary lymphedema (SL), a new thought and a new method are developed for treatment of the SL, and the problem that the SL lacks an effective treatment means is effectively solved.
Owner:JILIN UNIVERSITY

Combined traditional Chinese medicine composition for treating tumors by improving tumor immune microenvironment and application of combined traditional Chinese medicine composition

The invention relates to a combined traditional Chinese medicine composition for treating tumors by improving a tumor immune microenvironment and application thereof. The combined traditional Chinese medicine composition comprises rhein and hesperidin. Rheinic acid and hesperidin have stronger antitumor activity than single components in combined application, and the combined pharmaceutical composition can significantly inhibit the growth of cancer-related fibroblasts, reduce CCL2 secreted by cancer-related adipocytes and increase infiltration of CD8 + T cells at tumor sites, so that the growth of tumors is significantly inhibited, and the antitumor effect is improved. And a new method and thought are provided for combined treatment of cancers.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Biomarker-based treatment and diagnostic methods for il-17-dependent conditions

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, P13, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.
Owner:MOONLAKE IMMUNOTHERAPEUTICS AG

Pharmaceutical composition for treating neuropathic pain

Disclosed is a pharmaceutical composition for treating and / or preventing central neuropathic pain, the pharmaceutical composition containing at least one component selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor. Also disclosed is a pharmaceutical composition for treating and / or preventing neuropathic pain, the pharmaceutical composition containing at least one component selected from the group consisting of a JAK / STAT inhibitor, a CCL2 inhibitor, and an MMP2 inhibitor and being to be administered at intervals of 6 days or more.
Owner:OSAKA UNIVERSITY

Method for repairing wound by activating fibroblasts

The invention provides a method for repairing a wound surface by activating fibroblasts. Specifically, the invention provides a nanofiber mat, the nanofiber mat continuously delivers curcumin to activate fibroblasts, and the activated fibroblasts further utilize an EMMPRIN and CCL2 target mediated pathway to complete the repair of a steady-state basement membrane. Experimental results show that the delivery mode can effectively activate fibroblasts, and the activated fibroblasts regenerate skin by inhibiting expression of EMMPRIN and CCL2 targets and promoting expression of laminin, so that acute wounds and chronic wounds are treated. The invention also provides a method for preparing the nanofiber mat.
Owner:SHANGHAI JIAOTONG UNIV

A group of diagnostic markers for aortic dissection and their applications

The present invention discloses a set of diagnostic markers for aortic dissection and their applications. The markers include the genes MMP8, ALOX15, HP, FXYD2, SIGLEC8, and CCL2. The genes MMP8, ALOX15, HP, FXYD2, SIGLEC8, and CCL2 protected by the present invention can be used as biomarkers for AD and as indicators for assessing disease severity in AD patients, enabling efficient diagnosis of patients with aortic dissection.
Owner:NANJING FIRST HOSPITAL

CCL2 and receptor specific binding polypeptide thereof, and application of CCL2 and receptor specific binding polypeptide in prevention and treatment of cholestatic liver disease

The invention discloses CCL2, a receptor specific binding polypeptide thereof and application of the receptor specific binding polypeptide in prevention and treatment of cholestatic liver diseases, and relates to the technical field of biological medicines. The CCL2 and the receptor specific binding polypeptide thereof, which are screened by a molecular simulation technology, can be specifically bound with a key molecule CCL2 for inducing diseases and a plurality of receptors thereof in a cholestatic liver disease occurrence process, so that liver function indexes are recovered; the traditional Chinese medicine composition can be used for relieving liver pathological injury, including inhibiting bile duct hyperplasia, relieving portal vein inflammatory response and relieving portal vein fibrosis, so that the pathological development process of fibrosis and inflammation caused by the liver injury is blocked.
Owner:WUHAN UNIV

Biomarker-based treatment and diagnostic methods for il-17-dependent conditions

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.
Owner:MOONLAKE IMMUNOTHERAPEUTICS AG

Application of crocin A in the preparation of drugs for treating IgA nephropathy

This invention relates to the field of biomedical technology, and particularly to the application of crotonin A in the preparation of drugs for treating IgA nephropathy. Pharmacodynamic experiments conducted in vivo on a Thy1 rat model showed that crotonin A effectively reduced 24-hour urinary protein and the urinary protein-to-creatinine ratio in an IgA nephropathy model—an anti-Thy1 rat nephritis model—and inhibited the expression of mRNAs of genes related to renal cortical inflammation, proliferation, and fibrosis, including Cyclin E, α-SMA, FN, CCL2, NF-κB, and IL-6, further improving renal pathology. In in vitro cell models, crotonin A inhibited the proliferation of rat mesangial cells and suppressed the expression of mRNAs of TGF-β, Cyclin E, α-SMA, CCL2, NF-κB, and IL-6, indicating that crotonin A has significant anti-inflammatory, anti-cell proliferation, and anti-fibrotic effects. Brucella oleracea has considerable therapeutic potential, providing a potential new drug option for the clinical prevention and treatment of IgA nephropathy, and is of great significance for the development of safe and effective drugs for the treatment of IgA nephropathy.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Application of vitepofen in preparation of medicine for treating psoriasis

The invention provides application of vitepofen in preparation of a medicine for treating psoriasis, and belongs to the technical field of biological medicine. The invention finds that the vitepofen can obviously inhibit the proliferation of keratinocytes, has an inhibition effect on the expression of psoriasis related inflammatory factors CXCL1 / CXCL2 / CXCL8, CCL2 / CCL20 and IL-1beta, and has an inhibition effect on the phosphorylation of STAT3 and NF-kappa B. In general, the vitepofen can simultaneously inhibit keratinocyte proliferation and psoriasis-like inflammatory response, and can be used for preparing the medicine for treating psoriasis.
Owner:PEKING UNIVERSITY SHENZHEN HOSPITAL

Synthesis method of histone deacetylase 4 small-molecule inhibitor and application of histone deacetylase 4 small-molecule inhibitor in resisting vascular endothelial aging

The invention relates to a synthesis method of a histone deacetylase 4 small-molecule inhibitor and application of the histone deacetylase 4 small-molecule inhibitor in resisting vascular endothelial aging. A novel HDAC4 small-molecule inhibitor is synthesized by a simple and efficient novel method, and the structural formula of the inhibitor is shown in the specification. The HDAC4 small-molecule inhibitor has strong affinity with HDAC4, can obviously reduce the expression quantity of HADC4 and P21 proteins and mRNA of vascular endothelial cells and the expression quantity of mRNA of inflammation-related proteins Il6, CCL2 and Il-1beta, has an obvious effect of resisting senescence of the vascular endothelial cells, has very good druggability and safety, and can be used for preparing an anti-aging medicine for preventing senescence of the vascular endothelial cells. The compound can be used for preparing medicines for treating vascular endothelial senescence and related diseases thereof. # imgabs0 #
Owner:MACAU UNIV OF SCI & TECH +1

Chemokine peptide cocktails and methods of use

Methods for treating or inhibiting fibrosis in a subject by administering specific chemokine cocktails are described. The chemokine cocktails include combinations of CXCL4, CXCL9, CXCL10, CXCL11 and / or CXCL12 proteins, or the combination of CXCL1 and CXCL8 proteins. Methods for increasing extracellular matrix (ECM) production and / or treating a wound in a subject by administering specific chemokine cocktails are also described. In these methods, the cocktails include CXCL1 and CXCL8 proteins and optionally further include a CCL2 protein.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION +1

Antibodies targeting CCR2

ActiveZA202402859B
The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.
Owner:GRANITE BIO AG

Application of beta-glucan in preparation of preparation for reducing expression quantity of related genes of skin extracellular matrix inflammation

The invention relates to application of beta-glucan in preparation of a preparation for reducing the expression quantity of related genes of skin extracellular matrix inflammation. The structure of the beta-glucan is formed by connecting structural units. The invention also provides a biomarker, the biomarker is a gene related to skin extracellular matrix inflammation, and the gene comprises any one or a combination of at least two of IL1A, IL1B, IL1R1, IL1RAP, IL6, NFKB2, FOSB, FOSL1, JUN, JUND, CCL2, PTGS2, MMP10, MMP12, MMP13, CXCL8, CD86, PLAU, GADD45A, TNFSF18, TNFRSF10B, TNFRSF12A, TNFRSF14 or TNFRSF21.
Owner:GUANGDONG MARUBI BIOLOGICAL TECH CO LTD

Application of ROS (reactive oxygen species) response type multifunctional nano-delivery drug in high myopia related anxiety disorder and preparation method of ROS response type multifunctional nano-delivery drug

PendingCN121466325AOrganic active ingredientsSenses disorderAptamerMononuclear cell infiltration
The invention relates to an application of an ROS (reactive oxygen species) response type multifunctional nano-delivery drug in preparation of a drug for treating anxiety disorder related to high myopia or high myopia, the drug is TK-F-PEI / siR-A, the drug takes ROS response TK-F-PEI as a carrier, a CCL2 nucleic acid aptamer is arranged on the surface of the carrier, and MMP9siRNA is packaged on the core of the carrier. The invention further provides a preparation method of the medicine. The composition can effectively relieve inflammatory response in high myopia, reduce monocyte infiltration to a central nervous system, target local damaged blood eye and blood brain barriers caused by high myopia through CCL2 / ROS double response, promote barrier repair and break vicious circle of inflammation by silencing MMP9 expression, thereby relieving anxiety symptoms of high myopia patients, and improving the treatment effect of the high myopia patients. The living quality of the patient is improved. The pharmaceutical preparation provided by the invention has the advantages of strong pertinence, obvious curative effect, small side effect and the like, provides a new thought and method for treatment of high myopia related complications, and has a wide application prospect.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Molecular markers for differential diagnosis of aortic dissection and acute myocardial infarction and their applications

The present invention discloses molecular markers for differential diagnosis of aortic dissection and acute myocardial infarction and their applications. The molecular markers include gene SIGLEC8, gene CCL2, gene PRR35, gene FAM240C, gene TNFAIP8L3, and gene ASTL. The genes SIGLEC8, CCL2, PRR35, FAM240C, TNFAIP8L3, and ASTL protected by the present invention can be used as biomarkers for differentiating aortic dissection and acute myocardial infarction. The markers protected by the present invention have the potential for good differential diagnosis of patients with aortic dissection and acute myocardial infarction, and have good diagnostic efficacy, which can distinguish patients with aortic dissection from those with acute myocardial infarction, enabling patients to receive effective treatment in a timely manner.
Owner:NANJING FIRST HOSPITAL

Biomarker-based treatment and diagnostic methods for il-17-dependent conditions

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.
Owner:MOONLAKE IMMUNOTHERAPEUTICS AG

Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
Owner:UNIV PARIS CITE +2

Drug-loaded biomimetic nanodecoys based on genetic engineering, their preparation methods and applications

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.
Owner:ZHEJIANG UNIV

Antibodies targeting CCR2

The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.
Owner:GRANITE BIO AG

Biomarkers with therapeutic implications for peritoneal cancer spread

The present invention relates to a method for detecting or determining the susceptibility of a subject with peritoneal carcinomatosis to treatment with an inhibitor of plasminogen activator inhibitor 1 (PAI-1), wherein the method comprises determining the concentration of PAI-1 in ascites and determining the level of phosphorylated tumor signal transducer and activator of transcription 3 (STAT3). The level of phosphorylated STAT3 can also be determined by measuring the concentration of one or more surrogate markers (such as IL-6, IL-10, CCL2, MMP9 and ANGPT1) in ascites.
Owner:SINGAPORE HEALTH SERVICES PTE LTD

Application of IAA in preparation of medicine for preventing and treating atherosclerosis

The invention belongs to the technical field of biological medicines, and particularly relates to application of IAA in preparation of a medicine for preventing and treating atherosclerosis. Atherosclerosis is caused by excessive deposition of cholesterol, and IAA can significantly reduce formation of aorta and aortic sinus lipid plaques of atherosclerosis model mice by adjusting monocyte chemotactic and adhesion functions (specifically, down-regulating expression of chemotactic factors CCL2 and CXCL1, receptors CCR1 and CCR2, adhesion molecules ICAM1 and the like). An injection preparation is preferably selected as a medicine dosage form, the intervention dosage of IAA is 50 mg / kg, and the intervention time is 15 weeks. The new application of IAA in prevention and treatment of atherosclerosis is explored for the first time, the action mechanism of IAA is clear, the intervention effect is remarkable, and a new target spot and thought are provided for developing safe and effective medicines and means for preventing and treating atherosclerosis.
Owner:NINGXIA MEDICAL UNIV

Improved production of angptl3 mimetics

The present invention pertains to the use of gene editing and miRNA technologies for improving recombinant production of ANGPTL3 mimetics in CHO cells. The gene expression modifications are used for knock-out / knock-down of the endogenous protein CCL2 of the CHO cells which is difficult to separate from ANGPTL3 mimetics during purification.
Owner:NOVARTIS AG

A dual-path nano-preparation targeting sclera, and a preparation method and application thereof

PendingCN122321160AAptamerCCL2
This invention discloses a dual-pathway nanoformulation targeting the sclera, its preparation method, and its applications. The nanoformulation uses ketithial-modified fluorinated polyethyleneimine (TK-F-PEI) as a carrier, with a core loaded with hypoxia-inducible factor-1α small interfering RNA (HIF-1α siRNA) and a surface-coupled chemokine CCL2 nucleic acid aptamer. After local ocular administration, this formulation can efficiently target scleral lesions in myopic eyes, neutralizing CCL2 through the aptamer to improve the scleral inflammatory microenvironment, while simultaneously releasing siRNA to silence HIF-1α to inhibit the intracellular hypoxia pathway, synergistically reversing pathological scleral remodeling and delaying axial elongation. This invention's formulation exhibits strong targeting, good safety, and significant efficacy, providing a novel combined targeted drug delivery strategy for the clinical treatment of myopia, especially high myopia.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Application of CCL2 / CCR2 signaling pathway blocker in relieving chemotherapeutic drug-induced cardiac injury

The invention discloses an application of a CCL2 / CCR2 signal channel blocker in relieving chemotherapeutic drug-induced heart injury, and belongs to the technical field of biological medicines. The invention finds that a CCL2 / CCR2 signal channel blocker, particularly a CCL2 neutralizing antibody, has an obvious effect of improving the chronic cardiotoxicity induced by the chemotherapeutic drug adriamycin, and also can cooperate with the therapeutic effect of the chemotherapeutic drug at the same time. On the basis, the invention provides a combined treatment strategy based on a CCL2 neutralizing antibody, and the cardiotoxicity problem and tumor drug resistance challenge in the clinical application of the adriamycin are solved at the same time through targeted regulation and control of a CCL2 signal channel.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Preparation of mucous membrane adjuvant for recruiting pre-DC and application of mucous membrane adjuvant in influenza vaccine

The invention relates to the field of immunology, in particular to preparation of a mucous membrane adjuvant for recruiting pre-DC and application of the mucous membrane adjuvant in influenza vaccines. Tridecafluoroheptyl ethylene oxide and mannose are grafted on polyethyleneimine, the polyethyleneimine and structural protein hemagglutinin of influenza viruses are adsorbed to form a nano vaccine MF25PEI / HA, secretion of CCL2 is promoted by activating a TLR4 pathway of nasal cavity cDC, pre-DC is recruited and differentiated into cDC, and the network steady state of the nasal cavity cDC is maintained. HA uptake is increased by targeting cDC, cDC maturation is stimulated, and high-level immune response is induced. After intranasal immunization of MF25PEI / HA, secretion of high-level IgA and IgG is caused, activation of B cells, T cells and Tfh cells is promoted, and differentiation of memory B cells and memory T cells is induced. Effective protection can be provided for the influenza H1N1 virus, and a new thought is provided for research and development of respiratory mucosa vaccines.
Owner:HENAN AGRICULTURAL UNIVERSITY

Improved production of angptl3 mimetics

PendingAU2025220507A1CCL2Cell biology
The present invention pertains to the use of gene editing and miRNA technologies for improving recombinant production of ANGPTL3 mimetics in CHO cells. The gene expression modifications are used for knock-out / knock-down of the endogenous protein CCL2 of the CHO cells which is difficult to separate from ANGPTL3 mimetics during purification.
Owner:NOVARTIS AG

Antibodies targeting CCR2

The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.
Owner:GRANITE BIO AG